The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Jul. 05, 2016

Filed:

Sep. 27, 2011
Applicants:

Ken-ichi Asai, Ibaraki, JP;

Kazuo Kawakami, Ibaraki, JP;

Masami Mochizuki, Ibaraki, JP;

Inventors:

Ken-ichi Asai, Ibaraki, JP;

Kazuo Kawakami, Ibaraki, JP;

Masami Mochizuki, Ibaraki, JP;

Assignee:
Attorneys:
Primary Examiner:
Assistant Examiner:
Int. Cl.
CPC ...
A61K 39/00 (2006.01); A61K 39/39 (2006.01); A61K 38/16 (2006.01); C07K 14/235 (2006.01); A61K 39/12 (2006.01); A61K 39/02 (2006.01);
U.S. Cl.
CPC ...
A61K 39/39 (2013.01); A61K 38/162 (2013.01); A61K 39/099 (2013.01); A61K 39/12 (2013.01); C07K 14/235 (2013.01); A61K 2039/52 (2013.01); A61K 2039/5252 (2013.01); A61K 2039/541 (2013.01); A61K 2039/543 (2013.01); A61K 2039/55594 (2013.01); C12N 2710/10034 (2013.01); C12N 2760/18034 (2013.01);
Abstract

Problem to be Solved: The present invention provides a novel mucosal adjuvant. Solution: The present invention provides a mucosal adjuvant composition containing at least a composition comprising molecules having a molecular weight in a range of 100 to 300 kDa obtained from cells or culture fluid of. Administration of the mucosal adjuvant composition to a non-human animal at a surface of the mucous membrane can enhance immunity at the surface of mucous membrane. Therefore preventive effects against trans-mucosal infection can be increased by administering an inactivated vaccine against trans-mucosal infection and the mucosal adjuvant composition to a non-human animal at a surface of mucous membrane. The present invention is effective for preventing trans-mucosal infections, including one or more infections of e.g., canine parainfluenza, canine adenovirus, canine coronavirus, canine parvovirus, canine distemper virus, canine herpesvirus, reovirus and pneumovirus.


Find Patent Forward Citations

Loading…